Ramakrishnan, V., Timm, M., Haug, J., Kimlinger, T., Wellik, L., Witzig, T., . . . Kumar, S. (2009). Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.

Ramakrishnan, V., M. Timm, JL Haug, TK Kimlinger, LE Wellik, TE Witzig, SV Rajkumar, AA Adjei, and S. Kumar. Sorafenib, a Dual Raf Kinase/vascular Endothelial Growth Factor Receptor Inhibitor Has Significant Anti-myeloma Activity and Synergizes With Common Anti-myeloma Drugs. 2009.

Ramakrishnan, V., et al. Sorafenib, a Dual Raf Kinase/vascular Endothelial Growth Factor Receptor Inhibitor Has Significant Anti-myeloma Activity and Synergizes With Common Anti-myeloma Drugs. 2009.